💊Dapirolizumab (DZP) is a novel CD40L inhibitor 💊Results from phase 3 trial in #SLE 💊Demonstrated improvement in disease activity & GC tapering 💊More pts on DZP achieved BICLA response vs PBO 💊DZP well tolerated AbL16 #ACR24 @RheumNow https://t.co/dtb8QFKvlN